title: Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
abstract: BACKGROUND
  The purpose of this study was to report the results of a phase III, 3-arm, randomized trial comparing conventional radiotherapy (RT) to concurrent chemoradiotherapy (CRT) and accelerated RT in advanced head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  One hundred eighty-six of 750 planned patients were randomized to receive one of the following treatment plans: RT (66-70 Gy/2 Gy fraction/5 fractions weekly; CRT of weekly cisplatin (30 mg/m(2) ) with the same RT dose; or accelerated RT alone of 66 to 70 Gy/2 Gy fraction/6 fractions weekly were available for analysis. The primary endpoint was locoregional control at 5 years.
  
  
  RESULTS
  The mean follow-up was 54 months. Among the 3 arms, CRT showed superior locoregional control (49%; p = .049). RT had lower grade ≥3 mucositis and late toxicity.
  
  
  CONCLUSIONS
  CRT is associated with significantly better locoregional control as compared to RT and accelerated RT with higher but acceptable acute and late toxicities.
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Sarbani
authors.initials: S
authors.lastname: Ghosh-Laskar
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Nikhil
authors.initials: N
authors.lastname: Kalyani
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Tejpal
authors.initials: T
authors.lastname: Gupta
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Ashwini
authors.initials: A
authors.lastname: Budrukkar
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Vedang
authors.initials: V
authors.lastname: Murthy
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Manju
authors.initials: M
authors.lastname: Sengar
authors.affiliation: Department of Head and Neck Surgical Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Devendra
authors.initials: D
authors.lastname: Chaukar
authors.affiliation: Department of Head and Neck Surgical Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Prathamesh
authors.initials: P
authors.lastname: Pai
authors.affiliation: Department of Head and Neck Surgical Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Pankaj
authors.initials: P
authors.lastname: Chaturvedi
authors.affiliation: Department of Head and Neck Surgical Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Anil
authors.initials: A
authors.lastname: D'Cruz
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
authors.forename: Jaiprakash
authors.initials: J
authors.lastname: Agarwal
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology; D010025:Osteoradionecrosis / Q000209:etiology; D011446:Prospective Studies; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D012720:Severity of Illness Index; D014987:Xerostomia / Q000209:etiology; D055815:Young Adult
chemical_list: D011838:Radiation-Sensitizing Agents; D002945:Cisplatin
keywords: accelerated radiotherapy; chemoradiotherapy (CRT); cisplatin; head and neck squamous cell carcinoma (HNSCC); radiotherapy (RT)